Table S2.
ANCOVA analysis of change from baseline to end point in ADHD-RS-IV total score by reason for stopping prior MPH treatment (LOCF; full-analysis set)
| Test vs comparator | LS mean (SE)* test | LS mean (SE)* comparator | Difference in LS mean treatment – comparator (95% CI) | Effect size (95% CI) | P-value |
|---|---|---|---|---|---|
| Combined efficacy failure | |||||
| GXRa vs placebob | −22.929 (3.9409) | −12.113 (3.4445) | −10.817 (−18.480 to −3.154) | 0.78 (0.22 to 1.35) | 0.006 |
| ATXc vs placebob | −17.405 (3.7057) | −12.113 (3.4445) | −5.292 (−12.735 to 2.150) | 0.38 (−0.15 to 0.92) | 0.161 |
| Safety/tolerability | |||||
| GXRd vs placeboe | −23.770 (4.1920) | −12.818 (3.6314) | −10.952 (−21.115 to −0.789) | 0.73 (0.05 to 1.42) | 0.035 |
| ATXd vs placeboe | −18.242 (4.1288) | −12.818 (3.6314) | −5.425 (−15.720 to 4.871) | 0.36 (−0.31 to 1.03) | 0.295 |
| Other reasons (excluding inability to pay for medication) | |||||
| GXRe vs placebof | −38.148 (4.5166) | −22.345 (4.0536) | −15.803 (−24.870 to −6.735) | 1.12 (0.44 to 1.80) | <0.001 |
| ATXg vs placebof | −23.179 (4.3409) | −22.345 (4.0536) | −0.834 (−10.158 to 8.491) | 0.06 (−0.56 to 0.68) | 0.859 |
Notes:
*
A negative difference in LS mean (active treatment – placebo) indicates a positive effect of the active treatment over placebo. Number of observations per group at visit 15:
a
24,
b
28,
c
27,
d
17,
e
18,
F
21, and
g
19. Reasons not mutually exclusive.
Abbreviations: ADHD-RS-IV, Attention-Deficit/Hyperactivity Disorder Rating Scale version IV; ANCOVA, analysis of covariance; ATX, atomoxetine; CI, confidence interval; GXR, guanfacine extended release; LOCF, last observation carried forward; LS, least squares; MPH, methylphenidate; SE, standard error.